What this domain asks
The managed lifecycle from intended use and process ownership through supplier assessment, risk analysis, configuration, testing, release, operation, access, incident, change, continuity, retirement, and retained evidence.
The domain should retain its own evidence, decision owner, materiality criteria, exception path, and consequence even when it shares organization identity, workflow, or technology with adjacent domains. Aggregation can support oversight; it should not erase the evidence behind different risks or operating outcomes.
Buyer questions
- What is the intended use and regulated process boundary?
- Which risks require which assurance activities?
- What supplier and configuration evidence is relied on?
- How are access incidents changes and performance reviewed?
- How will data and records remain accessible after migration or retirement?
Mapped workflows
Electronic Signatures Audit Trails And Record History
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for electronic signatures audit trails and record history within this domain.
Role Identity Access And Segregation-Of-Duties Controls
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for role identity access and segregation-of-duties controls within this domain.
API Integration And Enterprise Interoperability
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for API integration and enterprise interoperability within this domain.
Deployment Administration Change Control And Validation Support
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for deployment administration change control and validation support within this domain.
Authority context
21 CFR Part 11
Part 11 sets criteria under which FDA considers electronic records and signatures trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.
FDA Computer Software Assurance Guidance
The guidance describes a risk-based approach to establishing confidence in automation used for production or quality systems, including intended use, risk analysis, assurance activities, records, and appropriate testing.
EU GMP Annex 11
Annex 11 addresses risk management, personnel, suppliers, validation, data, accuracy checks, storage, printouts, audit trails, change, security, incident management, signatures, business continuity, and archiving.
Relevant operating models
- Enterprise LIMS And Laboratory-Informatics Suite
- Configurable Specialist And Midmarket LIMS
- Scientific-Data Platform And SDMS
- Chromatography And Analytical Data System
- Regulated Laboratory Execution And Manufacturing-Quality Platform
Evidence boundary
Lab Systems Index provides market, standards, regulatory, product, and operating research. It does not validate a computerized system, certify Part 11 or GxP compliance, accredit a laboratory, approve a method, determine scientific validity, interpret patient results, or replace laboratory, quality, validation, regulatory, security, legal, data-integrity, or scientific review. A provider's documented capability can identify a research candidate but cannot establish buyer-specific adequacy for this domain.